FORCE’s eXamining the Relevance of Articles for Young Survivors (XRAYS) program is a reliable resource for breast cancer research-related news and information. XRAYS reviews new breast cancer research, provides plain-language summaries, and rates how the media covered the topic. XRAYS is funded by the CDC.
A research study published in Genetics in Medicine earlier this year shows that women with mutations in MSH6 and PMS2, two Lynch syndrome genes, have a modest (2 to 3-fold) but significantly increased risk for breast cancer.
Lynch syndrome mutations have a known risk of colorectal, ovarian and uterine/endometrial cancer, as well as many other cancers. This is the first study to evaluate breast cancer risk in women with mutations in specific Lynch syndrome genes. (6/14/18)
In this follow-up, we update a recent XRAYS on expanded genetic testing in Jewish women with breast cancer. An expert in the field suggests a different interpretation of the original study than the authors. We examine the key differences in interpretation of the data. (6/7/18)
In a March 2018 article from breastcancercare.org, Juliet conveys her personal experience with a breast cancer diagnosis and her decision to not have her breasts reconstructed after her mastectomy. She details the emotional complexity of her thought process and the empowerment she felt in her decisions. (5/24/18)
This study in mice looked at how wound healing after surgery affects metastasis. Researchers found that wound healing caused changes in the mouse immune system that allowed some cancer cells to grow, but that treatment with a non-steroidal anti-inflammatory drug (NSAID) reduced inflammation and frequency of metastases. While this research is promising, it remains to be seen if similar effects occur in humans. (5/17/18)
Current breast cancer treatments can negatively affect cardiovascular health. Recently, the American Heart Association released its first scientific statement on cardiovascular disease and breast cancer. This statement includes a comprehensive overview of the prevalence of both diseases, shared risk factors, cardiotoxic effects of therapy and the prevention and treatment of cardiovascular disease in breast cancer patients. (5/2/18)